| 发明名称 | Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD) | ||
| 摘要 | The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells. | ||
| 申请公布号 | US9469855(B2) | 申请公布日期 | 2016.10.18 |
| 申请号 | US201514963319 | 申请日期 | 2015.12.09 |
| 申请人 | Hadasit Medical Research Services and Development Ltd. | 发明人 | Safadi Rifaat |
| 分类号 | A61K48/00;C07H21/02;C07H21/04;C12N15/113;A61K31/7088;A61K45/06;C12Q1/68;A61K31/713;A61K31/7105 | 主分类号 | A61K48/00 |
| 代理机构 | Roach Brown McCarthy & Gruber, P.C. | 代理人 | Roach Brown McCarthy & Gruber, P.C. ;McCarthy Kevin D. |
| 主权项 | 1. A method of treating and/or attenuating hepatocellular carcinoma in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of an agent capable of specifically inhibiting expression of a human NLGn4 gene product, said human NLGn4 gene product comprising SEQ ID NO: 2, and said agent comprising one or more siRNAs having a length of 20-25 base pairs and a sequence with at least 95% complementarity to at least a portion of SEQ ID NO: 2, thereby treating and/or attenuating the hepatocellular carcinoma. | ||
| 地址 | Jerusalem IL | ||